Dr. Jörg Spiekerkötter, Chairman of the Supervisory Board

Dr. Jörg Spiekerkötter is a member of PAION’s Supervisory Board since June 2007 and the Supervisory Board appointed Dr. Spiekerkötter as Chairman in May 2010. Dr. Jörg Spiekerkötter has many years of experience in the pharmaceutical industry where he has held executive positions in the areas of finance, law and human resources. Until May 2007, he was the Chief Financial Officer of Organon BioSciences N.V., Oss (Netherlands). He left after the acquisition of the company by the U.S. pharmaceutical company Schering-Plough. Until September 2006, he was the Chief Financial Officer at Schering AG in Berlin (Germany), and before that he was Head of the Legal Department at Hoechst Schering AgrEvo GmbH in Berlin (Germany). Dr. Spiekerkötter is Managing Partner of JSP-Invest GmbH and Chairman of Dr. Loges + Co. GmbH since August 2016. Dr. Spiekerkötter studied in Bielefeld (Germany), Lausanne (Switzerland) and Freiburg (Germany) and has a PhD in law. Until December 2010, he was the Chief Financial Officer of Conergy AG, Hamburg (Germany).

 

Other supervisory board memberships or similar positions:

  • Dr. Loges + Co. GmbH, Winsen (Luhe)/Germany, Chairman (since 1 August 2016)

Dr. Karin Louise Dorrepaal, Vice-Chairman of the Supervisory Board, Chairman of the HR & Nomination Committee

Dr. Karin Dorrepaal is a member of PAION’s Supervisory Board since October 2012. She has broad experience in the Life Science Industry. After four years as a research fellow at the Netherlands Cancer Institute, Dr. Dorrepaal received her PhD from the Free University of Amsterdam, Netherlands. She went on to study at the Rotterdam School of Management where she obtained an MBA. In 1990, Dr. Dorrepaal joined Booz Allen Hamilton, Management Consultants. She specialized in the pharmaceutical industry and advised major companies on issues regarding strategy, sales, marketing and supply chain. In 2000, Dr. Dorrepaal was appoin­ted Vice President of Booz Allen.

 

Other supervisory board memberships or similar positions:

  •  Gerresheimer AG, Düsseldorf/Germany, Member of the Supervisory Board
  • Almirall S.A., Barcelona/Spain, Member of the Board of Directors
  • Triton Beteiligungsberatung GmbH, Frankfurt/Germany, Member of the Triton Industry Board
  • Kerry Group plc, Tralee/Ireland, Non-executive director
  • Humedics GmbH, Berlin/Germany, Chairman
  • In 2004, the Supervisory Board of Schering AG appointed Dr. Dorrepaal to the Board of Executive Directors of Schering AG.
  • After Bayer AG acquired Schering AG, Dr. Dorrepaal left the company in 2006 and since that time she holds several non-executive roles in Germany, Ireland, Spain and The Netherlands.

 

 

John Dawson, Chairman of the Audit Committee

John Dawson is a member of PAION’s Supervisory Board since May 2014. From 1996 to 2007, he held senior management positions in the European opera­tions of Cephalon Inc., including from 2005, a management board position as Chief Financial Officer and Head of Business Development Europe. In his time at Cephalon he led many of the deals that built the European business to over 1,000 employees, taking the business from having no sales in 1998 to a turnover of several hundred million U.S. dollars. In 2005, he led the USD 360 million acquisi­tion of Zeneus by Cephalon. Between 1991 and 1996 he was Director of Finance and Administration of Serono Laboratories (UK) Limited.

John Dawson joined Oxford BioMedica as Non-executive Director in August 2008. He was then appointed Chief Executive Officer in October 2008.

Dr. Dr. Irina Antonijevic, Chairman of the R&D Committee

Dr. Dr. Irina Antonijevic is a member of PAION’s Supervisory Board since May 2017. 

Dr. Dr. Irina Antonijevic joined vasopharm GmbH in 2016 as Chief Medical Officer. She has more than 16 years of drug development experience in different pharmaceutical organizations, with a focus on neuropsychiatric and rare diseases. In her last role at Sanofi Genzyme in Cambridge (MA, USA), she oversaw multiple innovative clinical programs as Global Head Early Development Neurology and Ophthalmology. She completed her medical studies at the Technical University of Munich (1991), received her MD from the Max Planck Institute in Munich (1992) and her PhD from the University of Edinburgh, UK (1995). She completed her residency at the Max Planck Institute of Psychiatry in Munich and received her Venia Legendi from the Charité, Berlin, in 2004. Dr. Dr. Antonijevic has been a regular reviewer for the German Ministry of Research (BMBF) since 2006.

 

Other supervisory board memberships or similar positions:

  • 4SC AG, Planegg (Munich)

Dr. Chris Tanner

Dr. Chris Tanner is a member of PAION’s Supervisory Board since May 2017. 

Dr. Chris Tanner was a member of the Executive Board since 2005 and has been a member of the Supervisory Board of Cosmo Pharmaceuticals N.V. since 2006 for which he conducted the IPO as Chief Financial Officer and Head of Investor Relations. In 2015, Cosmo span off the daughter Cassiopea SpA where he also acts as Chief Financial Officer and Head of Investor Relations. Moreover, he is a member of the board of directors or advisory board (Beirat) of listed DKSH AG, Private Equity Holding AG and the private medtec companies Qvanteq AG and Joimax GmbH. From 1998 to 2001, he was a partner of Dr. Ernst Mueller-Moehl and co-founder of the 20 Minutes group of newspapers and founded A&A Active Investor, a SIX-listed investment company. From 1992 to 1998, he was the Head of Corporate Finance & Capital Markets at UBS in Zurich, and from 1976 to 1991 he had various functions in the Corporate Banking Department at UBS in Zurich, Madrid and Los Angeles. Dr. Tanner has a PhD in economics and a diploma as economist from the University of St. Gallen.

 

Other supervisory board memberships or similar positions:

  • Member of the Board and Head of the Audit Committee of DKSH AG
  • Member of the Board and Head of Compensation Committee of Private
  • Equity Holding
  • Member of the Board of CureVac AG, Tübingen
  • Member of the Board of Joimax GmbH (start up endoscopic back surgery)
  • Member of the Board of Qvanteq AG (start up bioactive stent developer)
  • Member of Wyss Zurich Evaluation Board